Novo Nordisk reports strong Phase 3 obesity drug data and EU haemophilia approval

Novo Nordisk announced that its experimental obesity drug CagriSema achieved average weight losses of about 20.7% and 21.0% in two lower‑dose regimens in a Phase 3 REDEFINE 9 trial, far exceeding the 2.0% loss seen with placebo. The company also received European Union marketing authorization for its haemophilia A therapy FREHEMGO and filed U.S. and EU applications for the sickle‑cell drug etavopivat. The news lifted the share price by roughly 2‑3% and came after the firm raised its full‑year 2026 adjusted revenue and profit growth outlook to a range of –2% to +2% at constant exchange rates.

The trial results suggest CagriSema could become a major revenue driver in the growing obesity market, which may boost future sales and earnings. The EU approval of FREHEMGO adds a new product to Novo Nordisk’s haemophilia portfolio, expanding its revenue base. The raised guidance signals management confidence despite modest growth expectations.

  • 1Novo Nordisk stock rose 2.7% to DKK 286.1.
  • 2CagriSema lower‑dose regimens (1.7 mg/1.7 mg and 1.0 mg/1.0 mg) produced estimated average weight loss of 20.7% and 21.0% at week 68.
  • 3Placebo participants lost 2.0% of body weight at week 68.
  • 467.8% of CagriSema recipients lost at least 5% of weight within eight weeks; early responders averaged 25.4% loss at week 68 versus 17.8% for slower responders.
  • 5EU marketing authorization was granted for FREHEMGO (denecimig).
  • 6Regulatory applications were submitted for etavopivat in the United States and Europe.

Sources